...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: something. anything.

Thier website indicates that they will be attending ASCO, the premier annual Oncology conference.  I was hoping to see them presenting something here, which is still a possibility at this time, I guess.

 

Does anyone recall if fthey have attended ASCO in the recent past?

Share
New Message
Please login to post a reply